Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

FDA Approves Extended-Release Amantadine (GOCOVRI™) for Treatment of Dyskinesia

Statement from the Parkinson's Foundation Medical Director, Michael Okun, MD

"Today, Adamas announces FDA approval of an extended release amantadine capsule called GOCOVRI. This drug will provide a practical once a day solution for dyskinesiaAbnormal, involuntary body movements that can appear as jerking, fidgeting, twisting and turning movements; frequently caused by dopaminergic medications to treat Parkinson’s. management and reducing "off" time. Patients who are currently well managed using multiple doses per day of generic amantadine for dyskinesia will not likely derive additional symptomatic benefits from switching to once a day dosing; however, patients experiencing side effects from amantadine may wish to discuss options with their neurologist.

Both GOCOVRI and generic amantadine use is linked to a risk of side effects such as dizziness, hallucinations or blotching on the skin of the legs.  If you are considering starting this medicine or switching to this medicine we recommend consulting with your doctor.

In an independent Parkinson's Foundation study prior to this approval, we found that generic amantadine use improved dyskinesia in patients.  However, amantadine use does have a risk of side effects including insomnia and hallucinations. GOCORVI has been designed to limit the risk of these complications and it will not carry generic amantadine's warning for insomnia."

Call our Helpline, 1-800-4PD-INFO, or visit www.GOCOVRI.com for more information.

About the Parkinson's Foundation

The Parkinson's Foundation is working toward a world without Parkinson's disease. Formed by the merger of National Parkinson Foundation (NPF) and the Parkinson's Disease Foundation (PDF), the mission of the Parkinson's Foundation is to invest in promising scientific research that will end Parkinson's disease and improve the lives of people with Parkinson's, and their families, through improved treatments, support and the best care. For more information, visit www.parkinson.org, or call (800) 4PD-INFO (473-4636).

About Parkinson's Disease (PD)

Affecting an estimated one million Americans and 10 million worldwide, PD is the second-most common neurodegenerative disease after Alzheimer's and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression) as well as non-motor symptoms (e.g., depression A mood disorder whose symptoms can include a persistent sad or empty mood, feelings of hopelessness or pessimism, irritability and loss of interest or pleasure in previously enjoyable activities. and anxiety A feeling of nervousness, worried thoughts and physical distress.). There is no cure for PD and 60,000 new cases are diagnosed each year in the United States alone.

# # #

Friday, August 25, 2017
NPF Celebrates the Life and the Legend of Muhammad Ali
Saturday, June 4, 2016

MIAMI — Today we mourn the loss and celebrate the life of Muhammad Ali, a longtime friend of the National Parkinson Foundation (NPF). Mr. Ali passed away at age 74 after being hospitalized for respiratory problems, a common complication in advanced Parkinson’s disease.

Parkinson’s Disease Foundation Marks Tenth Year of People with Parkinson’s Advisory Council
Tuesday, May 24, 2016

Patient Advisors Drive PDF Mission to Solve, Treat and End Parkinson’s

The Parkinson’s Disease Foundation® (PDF®) is pleased to mark the tenth year of its People with Parkinson’s Advisory Council and welcome five new members. Created in 2006, the council is made up of people living with Parkinson’s and care partners who drive PDF’s goals of ending the disease and improving the lives of those affected by it.

Fourth Annual Celebrate Spring Boston Raises $50,000 for Parkinson’s Disease Foundation
Tuesday, May 3, 2016

Boston Area Women Inspire Fellow Young Professionals to End Parkinson’s

FDA Approves Drug to Treat Parkinson’s Disease Psychosis
Friday, April 29, 2016

Today, the FDA approved Nuplazid (pimavanserin) as the first drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis, which affects up to 40% of people with Parkinson’s.

FDA Panel Backs Approval of Pimavanserin
Tuesday, March 29, 2016

Big News for Advanced Parkinson’s

Lea Dempsey, Seventh Grader from NJ, Designs Winning Parkinson’s Awareness T-Shirt
Thursday, March 24, 2016

A digital drawing by 13-year-old Lea Dempsey of Princeton, NJ, came out on top in the Parkinson’s Disease Foundation’s (PDF) Seventh Annual Parkinson’s Awareness T-Shirt Design Contest. In PDF’s “kids only” contest, Ms. Dempsey’s design was a contender along with 20 other submissions from children ages five to 15-years-old. Her design was chosen as the winner by the general public in an online vote.

National Parkinson Foundation Campaign Promotes the Power of Exercise During Parkinson’s Disease Awareness Month
Monday, March 21, 2016

The National Parkinson Foundation (NPF) launched the #Move4PD campaign in recognition of National Parkinson’s Disease Awareness Month today. The campaign’s goal is to highlight the importance of exercise for those with Parkinson’s disease (PD) and its positive effects on the brain.

Parkinson's Disease Foundation to Host Celebrate Spring New York on Thursday, April 7
Friday, March 18, 2016

The Young New Yorkers for the Fight Against Parkinson’s and the Parkinson’s Disease Foundation® (PDF®) will hold its ninth annual Celebrate Spring New York at Marquee located at 289 10th Avenue between 26th and 27th Streets in New York City on Thursday, April 7, 2016.   Proceeds from the evening will support PDF’s research programs.

PDF Champions Raise More Than $35,000 for Parkinson’s Research at Martinis & Bellinis Event
Monday, March 7, 2016

Norwood, NJ, resident Stephanie Goldman-Pittel and her fellow co-chairs from nearby communities raised more than $35,000 to benefit the Parkinson’s Disease Foundation (PDF) at Martinis & Bellinis, their third annual PDF Helping Hours event on March 3. More than 100 guests attended the event held at Harvest Bistro & Bar in Closter, NJ, to support Parkinson’s research.

Parkinson's Disease Foundation Launches Online Course for Occupational Therapy Practitioners
Tuesday, March 1, 2016

The Parkinson's Disease Foundation® (PDF®) is pleased to launch a new online course, Occupational Therapy: Across the Parkinson's Disease Continuum, to prepare occupational therapy practitioners who are caring for the growing population of people living with Parkinson's disease.

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.